Trial · NCT03790111
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | Safety Population / Responders, Central Reviewer | 12 | Participants | |
| Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | Safety Population / Non-Responders, Central Reviewer | 41 | Participants | |
| Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | Per Protocol Population / Responders, Central Reviewer | 12 | Participants | |
| Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | Per Protocol Population / Non-Responders, Central Reviewer | 30 | Participants | |
| Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | By Treatment Cycle Population / Responders, Central Reviewer | 12 | Participants | |
| Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | By Treatment Cycle Population / Non-Responders, Central Reviewer | 21 | Participants | |
| Project Overall Survival Rate at Month 6 | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 0.87 | 95% Confidence Interval 0.74 to 0.93 | Proportion of participants | |
| Overall Survival (OS) | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 17.667 | 95% Confidence Interval 11.567 to NA | Months | |
| Project Overall Survival Rate at Month 12 | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 0.60 | 95% Confidence Interval 0.45 to 0.72 | Proportion of participants | |
| Median Progression Free Survival | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 6.233 | 95% Confidence Interval 4.067 to 7.467 | Months | |
| Disease Control Rate (DCR), Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 33 | Participants | ||
| Disease Control Rate (DCR), Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 33 | Participants | ||
| Disease Control Rate (DCR), Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 35 | Participants | ||
| Overall (Objective) Response Rate (ORR), Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 7 | Participants | ||
| Overall (Objective) Response Rate (ORR), Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 7 | Participants | ||
| Overall (Objective) Response Rate, Central Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 7 | Participants | ||
| Summary of Duration of Progression Free Survival, Local Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 7.000 | 95% Confidence Interval 5.567 to NA | Months | |
| Progression Free Survival, Local Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 7.467 | 95% Confidence Interval 5.567 to 10.533 | Months | |
| Progression Free Survival, Local Radiologist's Assessment | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 7.467 | 95% Confidence Interval 5.567 to 10.533 | Months | |
| Overall (Objective) Response Rate, Local Read | Xermelo 250mg Plus 1L Therapy for a Week, Then Xermelo 500mg | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03790111/results